BioXcel Therapeutics, Inc.

NasdaqCM:BTAI Stock Report

Market Cap: US$19.1m

BioXcel Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:BTAI Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
05 Jun 24SellUS$405,135BioXcel CorporationCompany252,028US$1.63

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of BTAI?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders533,5911.08%
Institutions3,405,1156.86%
Private Companies7,685,50115.5%
General Public38,004,74176.6%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 69.5%.

Top Shareholders

Top 25 shareholders own 22.6% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.5%
BioXcel Corporation
7,685,501US$3.0m0%no data
2.42%
The Vanguard Group, Inc.
1,201,377US$463.1k23.8%no data
0.73%
BlackRock, Inc.
362,486US$139.7k-17.7%no data
0.6%
Geode Capital Management, LLC
298,043US$114.9k11.7%no data
0.42%
Peter Mueller
209,795US$80.9k-9.8%no data
0.37%
Wells Fargo & Company, Securities and Brokerage Investments
185,058US$71.3k38.4%no data
0.37%
AVANT Fund Management
184,375US$71.1k0%100.0%
0.26%
Renaissance Technologies LLC
129,869US$50.1k0%no data
0.26%
Millennium Management LLC
128,773US$49.6k4.91%no data
0.16%
David Mack
81,267US$31.3k0%no data
0.16%
Merrill Lynch & Co. Inc., Banking Investments
79,688US$30.7k14.7%no data
0.16%
State Street Global Advisors, Inc.
77,149US$29.7k-38.2%no data
0.14%
Saint Olive Gestion
70,000US$27.0k0%no data
0.12%
Vimal Mehta
61,605US$23.7k14.8%no data
0.11%
David Mack
54,178US$20.9k0%no data
0.099%
Jane Street Group, LLC, Asset Management Arm
49,317US$19.0k-60.6%no data
0.089%
BNP Paribas Arbitrage Sa, Asset Management Arm
44,381US$17.1k-83.8%no data
0.082%
Northern Trust Global Investments
40,749US$15.7k-79.1%no data
0.082%
Morgan Stanley, Investment Banking and Brokerage Investments
40,598US$15.6k-46.1%no data
0.082%
Arete Wealth Advisors, LLC
40,500US$15.6k-6.9%no data
0.081%
Hennion & Walsh Asset Management, Inc.
40,099US$15.5k-1.23%no data
0.081%
Diversify Wealth Management, LLC
40,000US$15.4k0%no data
0.08%
Alean (Capital) AG
39,753US$15.3k0%0.01%
0.077%
Cambridge Investment Research Advisors, Inc.
38,050US$14.7k0%no data
0.069%
Susquehanna International Group, LLP, Asset Management Arm
34,207US$13.2k-80.3%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 08:09
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioXcel Therapeutics, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Guyn KimBMO Capital Markets Equity Research
Alec StranahanBofA Global Research